Dirk Heerwegh

发表

Durability of antibody responses elicited by a single dose of Ad26.COV2.S and substantial increase following late boosting

Mathieu Le Gars, H. Schuitemaker, D. Heerwegh, 2021, medRxiv.

Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine

H. Schuitemaker, P. van Damme, M. McElrath, 2021, The New England journal of medicine.

Durable Humoral and Cellular Immune Responses 8 Months after Ad26.COV2.S Vaccination

H. Schuitemaker, D. Heerwegh, J. Sadoff, 2021, The New England journal of medicine.

Face-to-Face versus Web Surveying in a High-Internet-Coverage Population Differences in Response Quality

Geert Loosveldt, Dirk Heerwegh, G. Loosveldt, 2008 .

Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19.

Ahmed Abdul Azim, D. Lauffenburger, H. Schuitemaker, 2021, JAMA.

Ad35.CS.01 - RTS,S/AS01 Heterologous Prime Boost Vaccine Efficacy against Sporozoite Challenge in Healthy Malaria-Naïve Adults

W. Ballou, Joe D. Cohen, E. Jongert, 2015, PloS one.

Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans

H. Schuitemaker, R. Baric, M. Lifton, 2021, Nature.

Mode Differences Between Face-to-Face and Web Surveys: An Experimental Investigation of Data Quality and Social Desirability Effects

Dirk Heerwegh, D. Heerwegh, Dirk Heerwegh, 2009 .

Minimizing survey refusal and noncontact rates: do our efforts pay off?

Geert Loosveldt, Dirk Heerwegh, Koenraad Abts, 2007 .

ICT learning experience and research orientation as predictors of ICT skills and the ICT use of university students

Jef C. Verhoeven, D. Heerwegh, K. Wit, 2014, Education and Information Technologies.

Vaccines based on replication incompetent Ad26 viral vectors: Standardized template with key considerations for a risk/benefit assessment

Robert T. Chen, Roy G van Heesbeen, H. Schuitemaker, 2020, Vaccine.

Non-human primate to human immunobridging demonstrates a protective effect of Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola

H. Schuitemaker, D. Heerwegh, R. Roozendaal, 2022, npj Vaccines.

Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in children and adolescents in Africa: A randomised, placebo-controlled, multicentre Phase II clinical trial

M. McElrath, O. Anzala, D. Heerwegh, 2022, PLoS medicine.

Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trial

S. Lees, D. Watson-Jones, B. Lowe, 2021, The Lancet. Infectious diseases.

Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial

S. Lees, D. Watson-Jones, B. Lowe, 2021, The Lancet. Infectious diseases.

Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: A randomised, placebo-controlled Phase II clinical trial in Africa

M. McElrath, O. Anzala, D. Heerwegh, 2021, PLoS medicine.

A Double-Blind, Randomized, Placebo-Controlled Phase 1 Study of Ad26.ZIKV.001, an Ad26-Vectored Anti–Zika Virus Vaccine

Conor P. Cahill, H. Schuitemaker, L. van der Fits, 2021, Annals of Internal Medicine.

Effects of Personal Salutations in E-mail Invitations to Participate in a Web Survey

D. Heerwegh, Dirk Heerwegh, 2005 .

Safety and immunogenicity of the Ad26.COV2.S COVID-19 vaccine candidate: interim results of a phase 1/2a, double-blind, randomized, placebo-controlled trial

Mathieu Le Gars, H. Schuitemaker, P. van Damme, 2020, medRxiv.

Sources of Euroscepticism: Utilitarian Interest, Social Distrust, National Identity and Institutional Distrust

D. Heerwegh, Mark Swyngedouw, Koenraad Abts, 2009 .

The effect of personalization on response rates and data quality in web surveys

G. Loosveldt, D. Heerwegh, K. Matthijs, 2005 .

Safety and immunogenicity of RTS,S/AS01 malaria vaccine in infants and children with WHO stage 1 or 2 HIV disease: a randomised, double-blind, controlled trial.

M. Hamel, S. Kariuki, M. Oneko, 2016, The Lancet. Infectious diseases.

Explaining Response Latencies and Changing Answers Using Client-Side Paradata from a Web Survey

Dirk Heerwegh, Dirk Heerwegh, 2003 .

An experimental study on the effects of personalization, survey length statements, progress indicators, and survey sponsor logos in web surveys

Geert Loosveldt, Dirk Heerwegh, G. Loosveldt, 2006 .

Ad35.CS.01 - RTS,S/AS01 Heterologous Prime Boost Vaccine Efficacy against Sporozoite Challenge in Healthy Malaria-Naïve Adults

W. Ballou, E. Jongert, M. Lievens, 2015, PloS one.

Assessing Mode Effects in a National Crime Victimization Survey using Structural Equation Models: Social Desirability Bias and Acquiescence

G. Loosveldt, D. Heerwegh, Dirk Heerwegh, 2011 .

An Investigation of the Effect of Lotteries on Web Survey Response Rates

Dirk Heerwegh, Dirk Heerwegh, 2006 .

Risk of COVID-19 after natural infection or vaccination

Nicole L. Nollen, Eric A. Meyerowitz, Waseem M. Chughtai, 2023, EBioMedicine.

Personalizing E-mail Contacts: Its Influence on Web Survey Response Rate and Social Desirability Response Bias

G. Loosveldt, D. Heerwegh, Dirk Heerwegh, 2007 .

Durable antibody responses elicited by 1 dose of Ad26.COV2.S and substantial increase after boosting: 2 randomized clinical trials

H. Schuitemaker, D. Heerwegh, J. Sadoff, 2022, Vaccine.